Can-Fite BioPharma (CANF) jumps 18% in premarket action.
The company says a Phase 2b study of the A3AR agonist CF101 in RA "met all primary efficacy endpoints."
ACR20 response rates: CF101, 49%; placebo, 25%; p=0.035.
Responses were cumulative, indicating "a consistent anti-inflammatory effect."
The company calls the treatment's safety profile "excellent." (PR)